<DOC>
	<DOCNO>NCT01394666</DOCNO>
	<brief_summary>The purpose study evaluate treatment pattern associate outcomes CP-CML patient fail Imatinib 400 mg daily real-world setting .</brief_summary>
	<brief_title>Non-interventional Treatment Patterns Study Chronic Phase Chronic Myelogenous Leukemia ( CP-CML )</brief_title>
	<detailed_description>Time Perspective : Retrospective Prospective</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Leukemia , Myeloid , Chronic-Phase</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com . Adult patient ( 18 year old ) Chronic phase CML patient treat Imatinib 400 mg fail .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>